On 22 November 2018, orphan designation (EU/3/18/2059) was granted by the European Commission to IntraBio Ltd, United Kingdom, for acetylleucine for the treatment of spinocerebellar ataxia.
The sponsorship was transferred to IntraBio Ireland Ltd, Ireland, in April 2019.
|Disease / condition||
Treatment of spinocerebellar ataxia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.